Immune Neonatal Thrombocytopenia (NAIT)

Overview Of Neonatal Thrombocytopenia

• Defined as platelet count <150,000/μL.
• Relatively common; occurs in 1-3% of healthy term infants and 20-30% of neonatal intensive care unit populations.
• Healthy neonates exhibit higher thrombopoietin (TPO) levels; fetal megakaryocytes possess higher proliferative potential but lower ploidy.
• Primary immune-mediated disorders involve transplacental passage of maternal IgG antibodies causing accelerated fetal/neonatal platelet destruction.

Neonatal Alloimmune Thrombocytopenia (NAIT)

Incidence And Pathophysiology

• Most common cause of severe neonatal thrombocytopenia.
• Incidence: 1 in 500-1000 births for mild cases; 1 in 3000-5000 births for counts <50,000/μL.
• Platelet analog of hemolytic disease of fetus and newborn (Rh incompatibility).
• Fetal platelets express paternally inherited platelet-specific antigens absent on maternal platelets.
• Maternal immune system generates IgG alloantibodies crossing placenta, targeting and destroying fetal platelets.
• Implicated antigens: Human Platelet Antigen (HPA)-1a accounts for 75-80% of cases; HPA-5b accounts for 10-20%. HPA-4 important in Asian populations.
• Maternal human leukocyte antigen (HLA)-DRB30101 confers 25-fold increased risk of HPA-1a alloimmunization.
• Affects firstborn infants in 50% of severe cases (unlike Rh incompatibility); sensitization may occur via syncytiotrophoblast receptors early in pregnancy.

Clinical Manifestations And Complications

• Typically affects otherwise healthy, full-term neonates.
• Severe symptomatic thrombocytopenia: generalized petechiae, ecchymoses, cephalohematoma, umbilical bleeding, gastrointestinal/renal hemorrhage.
• Platelet count extremely low at birth, typically <50,000/μL (except HPA-5b incompatibility, which is less severe).
• Intracranial hemorrhage (ICH) incidence: 10-20%.
• ICH characteristics: Frequently severe, intraparenchymal, occurs in utero, detectable on prenatal ultrasonography. May cause intrauterine fetal demise.
• Spontaneous resolution typically occurs within 2-4 weeks as maternal IgG decays.

Diagnostic Evaluation

• Consider NAIT in all neonates with unexplained thrombocytopenia <50,000/μL or family history of transient neonatal thrombocytopenia.
• Platelet transfusion response (or lack thereof) provides no diagnostic utility.
• Definitive testing: HPA typing of mother and father.
• Serologic testing: Evaluate maternal serum for platelet-specific alloantibodies (anti-HPA-1, 3, 5; anti-HPA-4 in Asian descent).
• Confirmation requires demonstrating parental antigen incompatibility concurrent with specific maternal alloantibodies.
• Urgent cranial ultrasonography mandatory to exclude ICH; magnetic resonance imaging (MRI) indicated for abnormal neurologic examination.

Management Of Affected Neonate

• Transfusion threshold: Maintain platelets >30,000/μL (or >50,000-100,000/μL in presence of life-threatening hemorrhage or known ICH).
• Platelet transfusion: 10-20 mL/kg. Random, unmatched donor platelets demonstrate high efficacy; maternal (washed) or specific antigen-negative platelets utilized only if randomly matched transfusions fail.
• Intravenous immunoglobulin (IVIG): 1 g/kg/day for 1-3 days.
• Corticosteroids: Intravenous methylprednisolone (1 mg every 8 hours) utilized conjunctively with IVIG.
• Radiologic surveillance: Repeat neuroimaging monthly for 3 months to monitor for late hydrocephalus.
• Follow-up: Monitor counts until complete normalization to exclude inherited thrombocytopenia syndromes.

Antenatal Management Of Subsequent Pregnancies

• Subsequent pregnancies face higher severity and earlier onset risks.
• Management requires specialized maternal-fetal medicine input.
• Ascertain paternal zygosity: Homozygous paternal status guarantees affected fetus; heterozygous status indicates 50% risk.
• Fetal typing: Noninvasive prenatal testing using cell-free fetal DNA (cffDNA) preferred over amniocentesis.
• Therapeutic regimen: Maternal IVIG infusions.
• Timing: Initiate at 12 weeks gestation for mothers with previously affected ICH pregnancy; initiate at 20 weeks for previously affected non-ICH pregnancy.
• Augmentation: Add or escalate corticosteroids if IVIG monotherapy proves insufficient.
• Delivery planning: Cesarean section recommended to minimize intrapartum ICH risk.

Neonatal Autoimmune Thrombocytopenia

Pathophysiology And Etiology

• Secondary to passive transplacental transfer of maternal autoantibodies.
• Target antigens: Common to both maternal and fetal platelets (primarily GPIIb/IIIa or GPIb/IX complexes).
• Associated maternal disorders: Immune thrombocytopenic purpura (ITP), systemic lupus erythematosus (SLE), autoimmune thyroiditis.
• Maternal history: Thrombocytopenia during pregnancy <100,000/μL (especially <50,000/μL). Mothers with prior splenectomy for ITP can transfer antibodies and produce affected neonates despite normal maternal platelet counts.
• Distinguish from gestational thrombocytopenia: Occurs in 5-10% of pregnancies, mild (70,000-100,000/μL), normalizes post-delivery, does not cause neonatal thrombocytopenia.

Clinical Manifestations And Complications

• Usually less severe than NAIT.
• Only 10-15% of neonates develop counts <50,000/μL.
• Platelet count trajectory: Frequently near normal at birth, progressively drops to clinically significant nadir over 1-3 days.
• Bleeding risk lower; ICH extremely rare (<1-2%).
• Duration: Resolves in 3-12 weeks.

Diagnostic Evaluation

• Evaluate maternal history and maternal platelet count.
• Monitor neonatal platelet count serially for 3-7 days to capture nadir and confirm stabilization or spontaneous recovery.
• Cranial ultrasonography indicated for all neonates with severe thrombocytopenia.

Management Strategy

• Threshold for treatment: Platelet count <30,000/μL or presence of significant hemorrhage.
• First-line pharmacotherapy: IVIG and intravenous methylprednisolone.
• Platelet transfusion: Unrelated donor platelets administered only for severe, life-threatening hemorrhage (often rapidly consumed).
• Feeding modification: If thrombocytopenia persists or worsens past day 5, trial discontinuation of breastfeeding (eliminates potential transfer of breast milk antibodies).
• Antenatal therapy: Unnecessary during pregnancy except under extraordinary maternal circumstances.

Clinical And Laboratory Differentiation

Feature	Alloimmune Thrombocytopenia (NAIT)	Autoimmune Thrombocytopenia (Maternal ITP)
Platelet Antigens	Antigens found on fetal platelets not present on maternal platelets (usually HPA-1a or HPA-5b)	Antigens common to both maternal and fetal platelets (usually GPIIb/IIIa and GPIb/IX)
Platelet Count	Often <20,000/μL	Birth counts often >50,000/μL
Time Of Presentation	Birth	Platelet count can be near normal at birth, then fall over 1-3 days
Maternal History	Normal platelet count, no history of ITP, SLE, or hypothyroidism. May have concurrent benign gestational thrombocytopenia	Low platelet counts (unless splenectomized). History of ITP, SLE, or hypothyroidism
Intracranial Hemorrhage	10-20%	<1-2%
Primary Treatment	Random donor platelets, IVIG, matched platelets	IVIG, Methylprednisolone, random platelets (only if active hemorrhage)
Resolution Timeframe	Usually 2-4 weeks	Usually 3-12 weeks

Differential Diagnosis Of Neonatal Thrombocytopenia

Thorough evaluation must exclude other significant causes of neonatal thrombocytopenia, categorized into early-onset (<72 hours) and late-onset (>72 hours) etiologies.

Early-Onset Etiologies (<72 Hours)

• Placental Insufficiency/Hypoxia: Preeclampsia, intrauterine growth restriction, maternal diabetes. Causes impaired megakaryopoiesis and elevated TPO. Nadir at days 3-4, recovers by days 7-10. No treatment usually required.
• Perinatal Asphyxia/DIC: Disseminated intravascular coagulation resulting in rapid consumption.
• Congenital Infections (TORCH): Cytomegalovirus (most common, affects 50-77%), toxoplasmosis, rubella, syphilis. Presents with microcephaly, hepatosplenomegaly, chorioretinitis, “blueberry muffin” rash.
• Aneuploidy/Genetic Syndromes: Trisomy 13, 18, 21. Down syndrome associated with transient myeloproliferative disorder (GATA1 mutation).
• Congenital Amegakaryocytic Thrombocytopenia (CAMT): Severe thrombocytopenia <50,000/μL. Normal marrow cellularity but absent megakaryocytes. Caused by MPL mutation. Evolves into aplastic anemia. Curative therapy requires hematopoietic stem cell transplant.
• Thrombocytopenia-Absent Radius (TAR) Syndrome: Bilateral radial anomalies with present thumbs. Associated with cow’s milk allergy. Thrombocytopenia improves after first year of life.

Late-Onset Etiologies (>72 Hours)

• Late-Onset Sepsis: Bacterial or fungal septicemia.
• Necrotizing Enterocolitis (NEC): Massive platelet consumption; severe thrombocytopenia predicts poor outcome.
• Thrombosis: Renal vein or hepatic vein thrombosis.
• Vascular Anomalies: Kasabach-Merritt phenomenon. Rapidly enlarging kaposiform hemangioendothelioma or tufted angioma causing platelet trapping, profound thrombocytopenia, and consumptive coagulopathy. High mortality. Treatment includes sirolimus, corticosteroids, or vincristine.